Description du projet
De meilleurs vaccins pour la vieillesse
L’objectif du projet ISOLDA, financé par l’UE, consiste à mettre au point de nouveaux vaccins contre des maladies virales pour les personnes âgées, en promouvant les réponses des lymphocytes T spécifiques au virus qui ciblent l’immunosénescence et l’inflammation liée à l’âge des lymphocytes T. Un consortium international évaluera le potentiel des immunomodulateurs, notamment des inhibiteurs des kinases approuvés pour d’autres applications, afin de renforcer les réponses immunitaires induites par les vaccins. Les meilleurs composés sélectionnés seront testés à l’aide de modèles animaux in vivo de vaccination contre les maladies virales. Afin d’obtenir la validation clinique du principe, les chercheurs se concentreront sur l’amélioration de l’efficacité des vaccins antigrippaux en appliquant un composé immunomodulateur sélectionné à partir d’études in vivo et ex vivo sur les formulations des vaccins actuels. ISOLDA entend fournir des solutions innovantes à la réduction de l’efficacité liée à l’âge des vaccins préventifs actuels contre les infections virales destinés à la population croissante de personnes âgées.
Objectif
ISOLDA aims at the development of improved vaccines for older adults against viral diseases with highest burdens at old age, by promoting virus-specific T cell responses in vaccinees over 65 years, using modulators of T cell immunosenescence and inflammageing. It builds on leading interdisciplinary expertise and knowledge of ISOLDA partners in virology, (onco-)immunology, ageing and immunosenescence, to assess the potential of immunomodulators, including kinase inhibitors licenced for other human use, to improve vaccine-induced immune responses and safety in older adults. ISOLDA partners have shown that these compounds may indeed restore key immunosenescent signatures. They will investigate ex-vivo signatures of immunological ageing and restoring potential of selected compounds on vaccine-induced immune responses against influenza virus, using PBMC from past and on-going adult and ageing human cohorts of influenza vaccinees. Cohorts of vaccinees and/or patients for tick-borne encephalitis, Middle-East respiratory syndrome and SARS-CoV-2 are also uniquely available to ISOLDA to demonstrate broad applicability of the approach. The most promising compounds will be tested in in-vivo animal models for vaccination against these diseases. As a proof of concept, ISOLDA will aim at improving the efficacy of a licensed vaccine against a respiratory virus, up to Phase I or II clinical trial with a lead immunomodulator compound or combination of compounds added to the vaccine formulations. The choice of Phase I or Phase II study design will depend on the compound, which will be selected based on results obtained upon prior in-vitro testing and in vivo testing in animal models. Promising SMKIs and/or oleic derivatives will be combined with a licensed MF59®-adjuvanted and a non-adjuvanted seasonal influenza vaccine for a Phase I, required to establish safety for this innovative combination. Alternatively, licensed MF59® will be selected as the lead compound, and administered as licensed seasonal influenza vaccines with and without MF59® and co-administered with licensed mRNA SARS-CoV-2 S vaccine. In this case, a Phase II study will be initiated to evaluate the immunogenicity in older adults aged 65 and older. ISOLDA will further build on new generation vaccines against MERS and/or COVID-19, such as replication-competent propagation-deficient replicons and MVA-MERS S recently developed by ISOLDA partners. Taken together, ISOLDA will address call SC1-BHC-14-2019, by providing innovative solutions to reduced efficacy and safety of preventive vaccines in the increasing population of older adults, against viral infections that have the highest impact in this age group.
Champ scientifique (EuroSciVoc)
CORDIS classe les projets avec EuroSciVoc, une taxonomie multilingue des domaines scientifiques, grâce à un processus semi-automatique basé sur des techniques TLN.
CORDIS classe les projets avec EuroSciVoc, une taxonomie multilingue des domaines scientifiques, grâce à un processus semi-automatique basé sur des techniques TLN.
- sciences médicales et de la santémédecine fondamentaleimmunologieimmunisation
- sciences naturellessciences biologiquesmicrobiologievirologie
- sciences médicales et de la santésciences de la santémaladie infectieusevirus à ARNcoronavirus
- sciences médicales et de la santémédecine fondamentalepharmacologie et pharmacieproduit pharmaceutiquevaccins
Vous devez vous identifier ou vous inscrire pour utiliser cette fonction
Mots‑clés
Programme(s)
Régime de financement
RIA - Research and Innovation actionCoordinateur
30559 Hannover
Allemagne